Literature DB >> 26806363

Risk of Death in Bullous Pemphigoid: A Retrospective Database Study in Finland.

Anna-Kaisa Försti1, Jari Jokelainen, Markku Timonen, Kaisa Tasanen.   

Abstract

Bullous pemphigoid (BP) is an autoimmune skin disease of elderly people, which is associated with increased mortality. The aim of this study was to investigate the standardized mortality ratio (SMR) for BP in Finland, and concomitant comorbidities and medications. This was a retrospective database study of all cases of BP diagnosed at the Department of Dermatology, Oulu University Hospital, Finland, between 1985 and 2012. A total of 198 immunologically confirmed cases of BP were found. One-year mortality was 16.7%, and SMR 7.56 (95% confidence interval (CI) 4.98-10.14). The most common comorbidities were cardiovascular diseases (76.3%) and neurodegenerative diseases (40.9%). Malignancies (8.6%) were associated with increased mortality (hazard ratio = 2.4, 95% CI 1.1-5.5, p = 0.047). A novel finding was that polypharmacy was very common in patients with BP, and the higher the number of drugs, the greater the mortality. In conclusion, the mortality for BP in Finland is 7.6-fold that of a reference population, and malignancies and polypharmacy are associated with increased mortality.

Entities:  

Mesh:

Year:  2016        PMID: 26806363     DOI: 10.2340/00015555-2347

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  7 in total

Review 1.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

2.  Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Yun-Ju Tsai; Yung-Tsu Cho; Chia-Yu Chu
Journal:  Am J Clin Dermatol       Date:  2022-05-17       Impact factor: 6.233

3.  Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.

Authors:  Yi-Di Liu; Yan-Hong Wang; Yi-Cong Ye; Wen-Ling Zhao; Li Li
Journal:  Arch Dermatol Res       Date:  2017-03-19       Impact factor: 3.017

Review 4.  Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature.

Authors:  Rikke Bech; Line Kibsgaard; Christian Vestergaard
Journal:  Front Med (Lausanne)       Date:  2018-09-04

Review 5.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

6.  Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis.

Authors:  Xianxia Chen; Yaqiang Zhang; Zhicheng Luo; Yujuan Wu; Taoxiang Niu; Jiayuan Zheng; Yuanyuan Xie
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

7.  Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea.

Authors:  Hyeon Woo Jeon; Sook Jung Yun; Seung-Chul Lee; Young Ho Won; Jee-Bum Lee
Journal:  Ann Dermatol       Date:  2017-12-26       Impact factor: 1.444

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.